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The postulated relation between sili-
cone breast implants and the risk of connective-tissue
and autoimmune diseases has generated intense
medical and legal interest during the past decade. The
salience of the issue persists, despite the fact that a
great deal of research has been conducted on this
subject. To provide a stronger quantitative basis for
addressing the postulated relation, we applied several
techniques of meta-analysis that combine, compare,




We searched data bases and reviewed ci-
tations in relevant articles to identify studies that met
prestated inclusion criteria. Nine cohort studies, nine
case–control studies, and two cross-sectional studies
were included in our meta-analyses. We conducted
meta-analyses of the results of these studies, both
with and without adjustment for confounding factors,
and a separate analysis restricted to studies of sili-
cone-gel–filled breast implants. Finally, we estimated
the annual number of new cases of connective-tissue




There was no evidence that breast im-
plants were associated with a significant increase in
the summary adjusted relative risk of individual con-
nective-tissue diseases (rheumatoid arthritis, 1.04 [95
percent confidence interval, 0.72 to 1.51]; systemic
lupus erythematosus, 0.65 [95 percent confidence in-
terval, 0.35 to 1.23]; scleroderma or systemic sclero-
sis, 1.01 [95 percent confidence interval, 0.59 to 1.73];
and Sjögren’s syndrome, 1.42 [95 percent confidence
interval, 0.65 to 3.11]); all definite connective-tissue
diseases combined (0.80; 95 percent confidence in-
terval, 0.62 to 1.04); or other autoimmune or rheu-
matic conditions (0.96; 95 percent confidence interval,
0.74 to 1.25). Nor was there evidence of significantly
increased risk in the unadjusted analyses or in the




On the basis of our meta-analyses,
there was no evidence of an association between
breast implants in general, or silicone-gel–filled breast
implants specifically, and any of the individual con-
nective-tissue diseases, all definite connective-tissue
diseases combined, or other autoimmune or rheu-
matic conditions. From a public health perspective,
breast implants appear to have a minimal effect on
the number of women in whom connective-tissue dis-
eases develop, and the elimination of implants would
not be likely to reduce the incidence of connective-tis-
sue diseases. (N Engl J Med 2000;342:781-90.)
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HE relation between silicone breast implants
and autoimmune or connective-tissue dis-
eases has been the focus of considerable





 Concern was aroused by early case re-
ports of connective-tissue disease in women who had





meta-analyses have failed to demonstrate an increased
risk of specific connective-tissue diseases (rheumatoid
arthritis, systemic lupus erythematosus, and sclero-
derma or systemic sclerosis) or connective-tissue dis-





 However, the meta-analyses to date leave





a meta-analysis that dealt with unadjusted estimates
of effect but did not consider the effect of adjustment









 performed analyses of adjusted
effects, but in neither study were formal statistical
tests of homogeneity among studies undertaken, nor
were analyses of the influence of individual studies
or combinations of studies conducted. None of these
meta-analyses focused exclusively on silicone-gel–
filled breast implants. Moreover, eight new studies of
the possible relation between silicone breast implants
and autoimmune conditions or connective-tissue dis-





not included in the previous meta-analyses.
We conducted a comprehensive series of meta-
analyses of the largest group of studies to date to in-
vestigate the possible relation between silicone breast
implants and the risk of autoimmune conditions or
connective-tissue diseases. Our study incorporated the
eight studies not included in the earlier meta-analy-
ses and had four principal objectives: to investigate
the relation between breast implants and connective-
tissue diseases by incorporating all eligible studies into
an unadjusted analysis; to consider the effect of po-
tential confounding factors in an adjusted analysis;
to search for sources of heterogeneity among the
studies with formal statistical tests and influence analy-
ses; and to perform a separate analysis focused exclu-





dition, we evaluated the public health effect of silicone
breast implants by estimating the annual number of
T
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new cases of connective-tissue disease that can be at-











 and we conducted a search of the literature that




 Sources included Med-
line (National Library of Medicine, Bethesda, Md.) from January
1966 through May 1998; Toxline (National Library of Medicine,
Bethesda, Md.) from January 1985 through May 1998; Current
Contents Search (Institute for Scientific Information, Philadelphia)
from July 1997 through May 1998; and Dissertation Abstracts
Online (University Microfilms International, Ann Arbor, Mich.)
from January 1992 through May 1998. In searches of Medline,
Toxline, and Current Contents Search, we used a combination of
key words for breast implants and connective-tissue diseases. Key
words for studies of breast implants included “breast implant,”
“breast augmentation,” “breast reconstruction,” “mammoplasty,”
and “mammaplasty,” with all possible suffixes allowed (e.g., “im-
plantation” and “implants”). Key words for connective-tissue dis-
eases included “rheumatic diseases,” “connective tissue disease,”
“autoimmune disease,” “systemic sclerosis,” “scleroderma,” “lupus,”
“dermatomyositis,” “sarcoidosis,” “rheumatoid arthritis,” “fibromy-
algia,” “Sjögren,” and “polymyositis.” A search of Dissertation Ab-
stracts Online was conducted with use of a combination of key
words for “breast implant” and “connective tissue disease.” All
searches were limited to studies of human subjects and reports pub-
lished in English; they produced 757 citations. We were unable









All the potentially relevant papers were reviewed independently
by the investigators. The criteria for inclusion in the meta-analyses
were the presence of an internal comparison group and the availabil-
ity of numbers for the construction of two-by-two tables to estab-
lish categories of disease and implants. In cases in which there was
more than one published report on the same population or group
of patients, the most recent article was selected for analysis. Stud-
ies reporting only information on symptoms and the frequency with
which individual symptoms appeared were excluded, since individ-




All the data were independently abstracted by two investigators
with the use of standardized data-abstraction forms. Disagreements
were resolved by discussion. The following information was sought
from each paper, although some papers did not contain all the in-
formation: first author’s name, year of publication, geographic lo-
cation of the study, source of funding for the study, type of study
design (cohort, case–control, or cross-sectional), study popula-
tion, sample size, source of subjects (private practice, tertiary care
center, or defined population), type of implant, date of implanta-
tion, reason for implantation (cosmetic or reconstructive), disease
diagnosis, case definition, date of diagnosis, method of data col-
lection (self-report or medical-record abstraction), average time
to onset of symptoms after implantation, control for confounding
factors by matching or adjustment, and relative risks or odds ra-
tios and 95 percent confidence intervals for individual connective-
tissue diseases and all connective-tissue diseases combined associ-
ated with all types of breast implants and with silicone-gel–filled




The following disease entities were included in the analyses: rheu-
matoid arthritis; systemic lupus erythematosus; scleroderma or sys-
temic sclerosis; Sjögren’s syndrome; dermatomyositis or polymy-
ositis; all definite connective-tissue diseases combined, as defined
in each study; and a category of other autoimmune or rheumatic
conditions. The category of other autoimmune or rheumatic con-
ditions included conditions, such as undifferentiated connective-
tissue disease or mixed connective-tissue disease, that did not fulfill
the diagnostic criteria of the classic autoimmune diseases or con-
nective-tissue diseases; this category also included signs and symp-
toms of autoimmune or rheumatic conditions, such as joint pain,




The disease variables were as follows: the presence or absence of
any of the five individual connective-tissue diseases, the presence or
absence of all definite connective-tissue diseases combined, and the
presence or absence of other autoimmune or rheumatic conditions.
The exposure variable was the presence or absence of any type of
breast implant. Women who had had direct injections of any ma-
terial into the breast, including silicone, were excluded from the
analysis. A separate analysis was conducted for implants described
in the individual studies as silicone-gel–filled breast implants.









The basic data used in the unadjusted analyses consisted of a se-
ries of two-by-two tables defined by the dichotomous exposure
and disease variables for each study. Because the numbers in some
cells of the two-by-two tables were small, exact analyses and con-





ses of the associations in two-by-two tables were combined to pro-





 Summary estimates of the odds ratio and associated tests
for homogeneity were calculated for all connective-tissue diseases
combined, for specific diseases, and for other autoimmune or rheu-
matic conditions. We used stratified analyses involving three di-
chotomous variables (cohort design vs. other study design, year
of diagnosis before 1992 vs. year of diagnosis 1992 or later, and
validation of disease through medical records vs. no validation of
disease through medical records), as well as influence analysis, to
search for sources of heterogeneity. Summary odds ratios were






Only studies that provided an adjusted estimate, either through
the use of appropriate methods of analysis or through matching
of variables in the study design, were considered in this analysis.
The data needed from each study were the estimated adjusted ef-
fect (either the adjusted relative risk or the adjusted odds ratio,
the latter being a good approximation of the adjusted relative risk
in the case of rare diseases) and its estimated standard error (often
obtained indirectly from the confidence interval reported in the
study). First, we decided whether the adjusted relative risks from
each study were estimating the same underlying association be-
tween exposure and disease. We used a chi-square test for homo-




 If the test for homogeneity
was not rejected at a P value «0.10, we computed an estimated
summary adjusted relative risk involving an inverse-variance–based
weighted average of the individual natural logarithms of the val-




 Larger studies producing estimated
adjusted effects with smaller standard errors were weighted more
heavily in the summary adjusted relative risks than smaller studies
with correspondingly larger standard errors. Using the same meth-
ods of analysis, we produced an additional meta-analysis of silicone-
gel–filled implants only. SAS statistical software (version 6.12, SAS
Institute, Cary, N.C.) was used to calculate the estimates of the













 and two cross-section-
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*CI denotes confidence interval.
†Adjustments were made for the variables listed.
‡“Other conditions” included discoid lupus, Raynaud’s phenomenon, CREST syndrome (consisting of calcinosis cutis, Raynaud’s phenomenon, esophageal dysfunc-
tion, sclerodactyly, and telangiectasia), psoriatic arthritis, ankylosing spondylitis, Reiter’s syndrome, fibromyalgia, osteoarthritis, hypothyroidism, multiple sclerosis, der-
matomyositis or polymyositis, and Crohn’s disease. A score for the degree of certainty of diagnosis was assigned, and any subject with more than 50 percent certainty
of any possible condition was included in the analysis.
§“Other conditions” included polymyalgia rheumatica and temporal arteritis (as defined by the following codes from the 
 
International Classification of Diseases, 8th
Revision
 
 [ICD-8]: 446.30–39); muscular rheumatism, fibrositis, and myalgia (ICD-8 codes 717.9 and 717.99); arthritis not further specified (ICD-8 code 715.99);
rheumatism not further specified (ICD-8 code 718.99); and connective-tissue disease not further specified (ICD-8 codes 734.91 and 734.99). Ratios of observed cases
to expected cases were calculated instead of estimates of relative risk.
¶“Any connective-tissue diseases” included rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, dermatomyositis or polymyositis, scleroderma or
systemic sclerosis, ankylosing spondylitis, psoriatic arthritis, polymyalgia rheumatica, vasculitis, arthritis associated with inflammatory bowel disease, and polychondritis.
¿“Joint swelling” included any swelling of joints for at least one week.
**“Other connective-tissue diseases” included polymyositis (ICD-8 code 716.10, 
 
International Classification of Diseases, 9th Revision
 
 [ICD-9] code 710E), polymy-
algia rheumatica (ICD-8 code 446.38, ICD-9 code 725), polyarteritis nodosa, temporal arteritis (ICD-8 code 446.30, ICD-9 code 446F), other specified connective-
tissue disease (ICD-8 code 734.98, ICD-9 code 710W), connective-tissue disease or collagenosis without further specification (ICD-8 codes 734.91 and 734.99.10,
ICD-9 code 710X), sarcoidosis (ICD-8 code 135, ICD-9 code 135), localized lupus (ICD-8 code 695.40, ICD-9 code 695E), ankylosing spondylitis (ICD-8 code
712.40, ICD-9 code 720A), fibromyalgia (ICD-8 codes 712.50, 717.98, and 718.99; ICD-9 code 729A), and psoriatic arthritis (ICD-8 code 696.00, ICD-9 codes
696A and 713D).
††Three of four groups in the study were retrospective cohorts; the fourth was a cross-sectional group.
‡‡“Other rheumatic conditions” included any rheumatic disease, musculoskeletal disease, connective-tissue disease not further specified, and any other form of ar-
thritis (excluding osteoarthritis and fibromyalgia), as reported by patients.
§§“Rheumatic disease” included mild cases of autoimmune syndrome requiring therapy, without convincing laboratory findings for an absolute diagnosis of an auto-
immune disease.































































































































‡ Alberta, Canada, 
1998
All women
All definite connective-tissue diseases combined
Rheumatoid arthritis
Systemic lupus erythematosus





























§ Denmark, 1997 All women
All definite connective-tissue diseases combined 
Rheumatoid arthritis
Systemic lupus erythematosus





















































** Sweden, 1998 All women
All definite connective-tissue diseases combined
Rheumatoid arthritis
Systemic lupus erythematosus
































†† Scotland, 1998 All women





Indication for implant, 











All definite connective-tissue diseases combined
Rheumatoid arthritis
Systemic lupus erythematosus


































Houston, 1993 All women


















Age, year of surgery
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 in our meta-analyses. The majority of
the studies were conducted in the United States, but


















characteristics of the cohort studies are presented in
Table 1, and those of the case–control and cross-sec-
tional studies in Table 2. The cohort studies, the two




evaluated multiple disease outcomes. The diagnosis
of definite connective-tissue disease was obtained from





 which used self-reported data. The diag-
nosis of other autoimmune or rheumatic conditions
was obtained from medical records for all studies ex-

















 The 95 percent confidence inter-
vals included 1 for all diseases in all studies, except




 (rheumatoid arthritis and
connective-tissue diseases: adjusted relative risk, 0.52;





 (any connective-tissue disease: ad-
justed relative risk, 1.24; 95 percent confidence in-
terval, 1.08 to 1.41; other connective-tissue diseases:
adjusted relative risk, 1.30; 95 percent confidence in-
terval, 1.05 to 1.62) (Table 2).
 
*CI denotes confidence interval.
†Adjustments were made for the variables listed.
‡This study was cross-sectional. “Mixed connective-tissue disease” was defined according to ICD-9 codes 710.9 and 711. Six of 12 cases of connective-
tissue disease were diagnosed before implantation.
§This study was cross-sectional. “Any connective-tissue disease” included all definite connective-tissue diseases and “other connective-tissue diseases.”
“Other connective-tissue disease” included mixed connective-tissue disease.
¶“Undifferentiated connective-tissue disease” was defined according to ICD-9 code 710.9. The diagnosis was assigned if the referring physician’s diagnosis
of the discharge code of Health Care Investment Analysts was undifferentiated connective-tissue disease or the patient had been given the diagnosis of
scleroderma, but did not meet the criteria of the American College of Rheumatology; the patient did not meet the diagnostic criteria for another connec-
tive-tissue disease; and a minimum of two signs, symptoms, or laboratory values suggestive of a connective-tissue disease were documented.






























































































































































Burns et al.28 Michigan, 1996 Scleroderma or systemic sclerosis 274/2 1184/14 0.95 (0.21–4.36) Age, birth year, 
race
Dugowson et al.29 Washington State, 1992 Rheumatoid arthritis 300/1 1456/12 0.41 (0.05–3.13) Age
Englert et al.30 Australia, 1996 Scleroderma or systemic sclerosis 286/3 253/4 1.00 (0.16–6.16) Socioeconomic
status, age, 
ethnicity




















































Hochberg et al.31 Baltimore; San Diego, 
Calif.; Pittsburgh, 1996
Scleroderma or systemic sclerosis 837/11 2507/31 1.07 (0.53–2.13) Age, race, geo-
graphic site
Lacey et al.13 Ohio, 1997 Scleroderma or systemic sclerosis 189/1 1043/10 1.01 (0.13–8.15) Age, birth year
Laing et al.14¶ Michigan, Ohio, 1996 Undifferentiated connective-tissue 
disease
205/3 2220/27 2.27 (0.67–7.71) Age, birth year
Strom et al.32 Philadelphia, 1994 Systemic lupus erythematosus 133/1 100/0 — Age
Teel17¿ Washington State, 1997 All connective-tissue diseases
Systemic lupus erythematosus
















Age, year of di-
agnosis, race
Wolfe33 Kansas, 1995 Rheumatoid arthritis 637/3 1134/4 1.35 (0.30–6.06) Age
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Table 3 presents estimated summary unadjusted
odds ratios, 95 percent confidence intervals, and P val-
ues for the test for homogeneity for each of the con-
ditions under study. For the evaluation of heteroge-
neity, the goal was to retain the largest number of
studies that had statistical evidence of homogeneous
estimates of effect, although we recognized that sta-
tistical analysis alone cannot rule out the possibility
of persisting heterogeneity among those studies. The
removal of the study by Friis et al.11 from the analysis
of all definite connective-tissue diseases combined and
scleroderma or systemic sclerosis produced statistical-
ly homogeneous estimates; the removal of the stud-
ies by Friis et al.11 and Sánchez-Guerrero et al.25 from
the analysis produced a homogeneous estimate for
other autoimmune or rheumatic conditions. In all
cases, the homogeneous estimate did not differ ma-
terially in size from the original estimate. In these
unadjusted analyses, the estimates of the summary
odds ratio were all less than 1, with the exception of
that for Sjögren’s syndrome: summary odds ratio, 1.10
(95 percent confidence interval, 0.74 to 1.58). For
each of the conditions analyzed, the findings provided
no evidence of an association between breast im-
plants and specific connective-tissue diseases or com-
bined connective-tissue diseases.
Table 4 provides two estimates of summary adjust-
ed relative risk for each condition; one estimate in-
cludes the results of the study by Hennekens et al.,12
and one does not. The large size of the study by Hen-
nekens et al., as compared with each of the other stud-
ies, accounted for its disproportionate weight, which,
in turn, created a summary estimate that is largely a
reflection of the adjusted relative risk found in that
study. When the study was included, the estimates of
summary adjusted relative risk were slightly elevated
for all connective-tissue diseases combined (1.14),
rheumatoid arthritis (1.15), scleroderma or systemic
sclerosis (1.30), Sjögren’s syndrome (1.47), and oth-
er autoimmune or rheumatic conditions (1.15). The
95 percent confidence intervals included 1, except
those for all connective-tissue diseases combined (1.01
to 1.28) and Sjögren’s syndrome (1.01 to 2.14). When
the study by Hennekens et al. was excluded, all esti-
mates of summary adjusted relative risks were associ-
ated with 95 percent confidence intervals that includ-
ed 1. The estimate of the summary adjusted relative
risk of Sjögren’s syndrome remained elevated (1.42),
but the 95 percent confidence interval (0.65 to 3.11)
clearly included 1.
The P values shown in the last column of Table 4
indicate whether the estimate of the adjusted relative
risk from the study by Hennekens et al.12 was signif-
icantly different from the summary estimate from the
other studies.21 For all definite connective-tissue dis-
eases combined and other autoimmune or rheumat-
ic conditions, the P values for this comparison were
0.003 and 0.08, respectively. These small values sug-
*Conditional maximum-likelihood estimates are presented, except for the categories of all connec-
tive-tissue diseases combined and rheumatoid arthritis, for which estimates by the Mantel–Haenszel
method are shown. Exact confidence intervals (CIs) are presented, except for the categories of all
connective-tissue diseases combined and rheumatoid arthritis, for which limits obtained with the
methods of Robins, Breslow, and Greenland are shown.
†Exact P values obtained by the method of Zelen are presented, except for the categories of all
connective-tissue diseases combined, rheumatoid arthritis, and other autoimmune or rheumatic con-
ditions, for which P values obtained with the Breslow–Day chi-square statistic are shown.
TABLE 3. ESTIMATES OF THE SUMMARY UNADJUSTED ODDS RATIO FOR THE ASSOCIATION 
BETWEEN BREAST IMPLANTS AND CONNECTIVE-TISSUE DISEASES.




RATIO (95% CI)* 
P VALUE FOR 
HOMOGENEITY†
All connective-tissue diseases combined
All studies







Rheumatoid arthritis 10 0.62 (0.52–0.73) 0.17
Systemic lupus erythematosus 8 0.63 (0.44–0.86) 0.24
Scleroderma or systemic sclerosis
All studies







Sjögren’s syndrome 8 1.10 (0.74–1.58) 0.56
Dermatomyositis or polymyositis 6 0.90 (0.55–1.39) 0.88
Other autoimmune or rheumatic conditions
All studies
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gest that the results were heterogeneous and further
support our decision to perform separate meta-analy-
ses with and without the data of Hennekens et al.12
There is a distinct and important pattern in the size
of the estimates of summary relative risk: the small-
est in size are the unadjusted values, the next small-
est are the adjusted values, excluding the results of
Hennekens et al.,12 and the largest values include the
results of that study (Fig. 1). The results from the
analysis of studies that included only silicone-gel–
filled implants appear in Table 5. All the estimates of
the summary adjusted relative risk were less than 1 for
all conditions considered, and they were all lower than
the corresponding estimates in Table 4.
DISCUSSION
We used several techniques of meta-analysis to eval-
uate the existing studies of the association between
breast implants and connective-tissue diseases. These
included both exact methods (unadjusted analysis)22
and approximate, large-sample methods (adjusted
analysis).21 There is no evidence in either the analysis
of unadjusted odds ratios or the analysis of adjusted
relative risks, excluding the results of the study by
Hennekens et al.,12 of a significantly increased risk of
any specific connective-tissue disease, all definite con-
nective-tissue diseases combined, or other autoim-
mune or rheumatic conditions. The estimated summa-
ry relative risks for scleroderma or systemic sclerosis,
rheumatoid arthritis, and systemic lupus erythemato-
sus are close to or less than 1. Although our estimate
of the summary adjusted relative risk for Sjögren’s
syndrome (1.42; 95 percent confidence interval, 0.65
to 3.11) was elevated, a diagnosis of Sjögren’s syn-
drome requires salivary-gland biopsy.35 Whether bi-
opsies were actually performed in the studies cited is
unknown; and there may therefore have been bias in
the size of the estimated summary adjusted relative
risk due to misclassification of disease.
Our analyses showed that the summary adjusted
relative risks that included the study by Hennekens
et al.12 were higher than the pooled results of the
other studies for all definite connective-tissue diseas-
es combined and for other autoimmune or rheumatic
conditions. The study by Hennekens et al. was sub-
ject to various methodologic problems, including the
lack of validation of disease diagnosis by review of the
medical records. Self-reports of connective-tissue dis-
ease are inaccurate; in one study of self-reported rheu-
matoid arthritis, the positive predictive value was only
20 percent.36 Furthermore, the intensive publicity
about the postulated adverse health effects of breast
*CI denotes confidence interval.
†P values for grouped data were obtained with a chi-square test; this test assessed whether the estimate of the ad-
justed relative risk for the study by Hennekens et al.12 was significantly different from the estimate of the summary ad-
justed relative risk for the other studies. Details about this global test for differences among groups can be found in
Greenland.21
TABLE 4. ESTIMATES OF THE SUMMARY ADJUSTED RELATIVE RISKS OF AN ASSOCIATION 
BETWEEN BREAST IMPLANTS AND CONNECTIVE-TISSUE DISEASES.















All connective-tissue diseases combined
All studies


































Scleroderma or systemic sclerosis
All studies


































Other autoimmune or rheumatic conditions
All studies
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Figure 1. Comparison of the Estimates of Summary Relative Risk Obtained from the Unadjusted and Adjusted Meta-Analyses.
The solid circles denote the values for the summary unadjusted relative risk and two values for adjusted relative risk, one (indicated
by the asterisks) including the study by Hennekens et al.12 and one excluding it. The horizontal lines extending to the right and left
of the black circles indicate the widths of the 95 percent confidence intervals (CIs). The variation in the confidence intervals is, for
the most part, a function of the different sizes of the samples.
































































*CI denotes confidence interval.
TABLE 5. ESTIMATES OF THE SUMMARY ADJUSTED RELATIVE RISKS OF AN ASSOCIATION 







P VALUE FOR 
HOMOGENEITY
All connective-tissue diseases combined (Burns 
et al.,28 Edworthy et al.,10 Englert et al.,30 Lacey 
et al.,13 Park et al.,16 Sánchez-Guerrero et al.25)
6 0.82 (0.46–1.46) 0.82
Rheumatoid arthritis (Edworthy et al.,10 Park et 
al.,16 Sánchez-Guerrero et al.25)
3 0.98 (0.40–2.37) 0.43
Systemic lupus erythematosus (Edworthy et al.10) 1 0.94 (0.17–5.23) —
Scleroderma or systemic sclerosis (Burns et al.,28 
Englert et al.,30 Lacey et al.13)
3 0.85 (0.32–2.25) 0.70
Sjögren’s syndrome (Edworthy et al.10) 1 0.99 (0.17–5.94) —
Other autoimmune or rheumatic conditions 
(Sánchez-Guerrero et al.,25 Schusterman et al.26)
2 0.61 (0.41–0.91) 0.68
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implants is likely to have made women with implants
more aware of their symptoms and to have resulted
in overreporting of disease among women with im-
plants as compared with women without implants,
thus potentially biasing the estimated effects upward.
These factors suggest that the summary adjusted rel-
ative risks that included the study by Hennekens et
al. were probably overestimates.
In general, the summary adjusted relative risks
should be more valid than the summary unadjusted
odds ratios. On the other hand, some of the studies
with low estimates of relative risk were selectively ex-
cluded from the adjusted analysis because they had
no cases of connective-tissue disease among women
with breast implants. The summary adjusted relative
risks calculated on the basis of the remaining studies
could be higher as a result of bias.
Information on potential confounders of the asso-
ciation between breast implants and connective-tis-
sue diseases was incomplete in many studies.37 How-
ever, when potential confounding factors other than
age, race, and year of study were evaluated, they had
little effect on the adjusted relative risks reported in
individual studies. Most of the specific connective-
tissue diseases do not have strong established risk fac-
tors other than sex, age, and race.38 Specific genetic
markers of susceptibility are recognized for some of
the connective-tissue diseases,38-41 but no informa-
tion on the basis of which to evaluate them was avail-
able in the epidemiologic studies. In addition, many
studies did not report whether the indication for im-
plantation was cosmetic or reconstructive, a difference
that may have affected the signs and symptoms the
subjects subsequently had. The two studies that in-
cluded sufficient data to analyze the effect of long la-
tency (10 or more years after implantation) on the in-
cidence of connective-tissue disease suggested that the
time since implantation was not predictive of the risk
of connective-tissue disease.12,25 Individual studies did
not provide adequate data on rupture or leakage of im-
plants for us to include these features as possible cor-
relates of the incidence of connective-tissue disease.
Publication bias is frequently cited as a reason for
lack of validity in meta-analyses.42 Publication bias
could occur if studies that found no association be-
tween exposure and disease were less likely to be sub-
mitted and accepted for publication than were stud-
ies that found a positive association. In fact, the results
of the majority of the studies included in our meta-
analyses were negative, as stated by the authors. None-
theless, we examined the potential for publication bias
by constructing a funnel plot in which the inverse of
the estimated variance of the natural logarithm of the
adjusted relative risk was plotted against the natural
logarithm of the adjusted relative risk for each dis-
ease.42 Funnel plots of our data showed no evidence
of publication bias for any of the disease entities we
studied (data not shown).
Given the results of the individual studies and our
summary adjusted relative risks, we do not have con-
vincing evidence that the underlying summary rela-
tive risk of connective-tissue disease in the popula-
tion of women with breast implants exceeds 1. On
the basis of calculations in which the standard errors
from the studies under consideration were used, our
study had approximately 80 to 90 percent power to
detect true summary relative risks of 1.5 to 2.0, when
all studies were included.18 However, when the study
by Hennekens et al.12 was excluded, the power of the
study to detect a summary relative risk «2.0 was
roughly 70 percent or less for scleroderma or sys-
temic sclerosis, systemic lupus erythematosus, and Sjö-
gren’s syndrome.18
We calculated the population attributable risk, the
proportion of cases of connective-tissue disease in a
population that may be caused by breast implants,
using standard formulas.43,44 To estimate the number
of cases of connective-tissue disease attributable to
implants, we used the summary adjusted relative risks
obtained from our meta-analyses that included the
study by Hennekens et al.,12 assumed the proportion
of women with breast implants in the United States
to be 1 percent, and multiplied the annual incidence
of disease (averages obtained from reports in the lit-
erature17,25,40,45-57) by the population attributable frac-
tion. Although we chose high estimates for the pro-
portion of women with breast implants and the
summary adjusted relative risks so as to maximize
the possible public health effect of breast implants in
our calculations, the estimated annual number of new
cases of connective-tissue disease that could be at-
tributed to breast implants was small. Among 10 mil-
lion women in the United States, 4.3 of 3303 new
cases of rheumatoid arthritis, approximately 0.1 of
526 new cases of systemic lupus erythematosus, 0.4
of 164 new cases of scleroderma or systemic sclero-
sis, 1.3 of 400 new cases of Sjögren’s syndrome, and
0.2 of 54 new cases of dermatomyositis or polymy-
ositis may be attributed to breast implants each year.
Despite the differences in the meta-analyses con-
ducted thus far, none, including the meta-analyses
reported here, have identified a significant associa-
tion between breast implants and connective-tissue
diseases. On the basis of the research to date, no as-
sociation is evident between breast implants and any
of the individual connective-tissue diseases, all con-
nective-tissue diseases combined, or the other auto-
immune or rheumatic conditions, with the possible
exception of Sjögren’s syndrome. The uncertainty of
the diagnosis of Sjögren’s syndrome makes the inter-
pretation of the estimated summary adjusted relative
risk questionable, however. The meta-analysis focus-
ing solely on silicone-gel–filled implants produced
lower summary estimates of the adjusted relative risks
for all the diseases than did the analyses based on all
types of breast implant. From a public health perspec-
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tive, breast implants appear to have a minimal effect
on the number of women in whom connective-tissue
diseases develop, and elimination of implants would
be unlikely to reduce the incidence of connective-tis-
sue diseases.
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